In the light of these discoveries, new therapeutics have been developed to target TNF. The consistent efficacy demonstrated by these agents for the treatment of immune-mediated arthritis has validated TNF as an important mediator of the chronic inflammatory events and structural damage that occur with the diseases involved. Three of these agents (etanercept, infliximab and adalimumab) have been approved by the United States Food and Drug Administration (FDA) over the last 10 years for treatment of moderately to severely active RA, AS and PsA (10) (11) (12) .
Etanercept (13) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fe portion of human IgG. Infliximab (14) is a chimeric IgGIK monoclonal antibody with an approximate molecular weight of 149.100 daltons. It is composed of human constant and murine variable regions. Adalimumab (15) is a recombinant fully human IgG 1 monoclonal antibody specific for human tumor necrosis factor (TNF). Adalimumab was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG I:k constant regions.
Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis are commonly thought of as inflammatory diseases that affect younger individuals (16) . Although the initial presentation of these diseases is common in a patient's twenties or thirties, they usually persist for the duration of the patient's life. In addition, up to one-third of patients with RA have disease onset after 60 years of age (17) . Older patients with any of these three diseases are more likely to have more severe disease with significant functional decline. They are also more likely to have comorbidities and use concomitant medications than patients who are younger. In patients with RA, AS or PsA, the introduction of anti-tumour necrosis factor (TNF)-a therapies such as etanercept, infliximab and adalimumab has had a significant impact in ameliorating the signs and symptoms of disease, improving patient function and inhibiting radiographic progression (10) (11) (12) . Anti-TNF-a therapies now have well recognized safety profiles that have been demonstrated in the usual clinical trial populations for these diseases (18) , but such populations under-represent patients > or =65 years of age.
This retrospective study aims to determine the safety profiles for etanercept, infliximab and adalimumab in patients of 65 years or more, undergoing anti-TNF treatment for an active inflammatory disease such as rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis, or for psoriasis, in normal clinical practice.
MATERIALS AND METHODS
In this multicenter retrospective study we analyzed data regarding the safety and tolerance of anti-TNF agents in a large cohort of elderly patients, aged 65 or more, affected by inflammatory arthrites such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Ankylosing Spondylitis (AS) and affected by dermatological diseases, such as psoriasis, and undergoing at least 1 injection in anti-TNF-a treatment.
We also divided our population by age, 65 to 70 years, 71 to 75 years, and 76 or more, in order to detect any differences between these subgroups of patients taking biologic disease-modifying anti-rheumatic drugs (DMARDs) in terms of adverse event incidence rates.
Demographical data, clinical data, including comorbidities, duration of treatment with anti-TNF agents and duration of disease, associated therapies for arthritis, psoriasis or other diseases in this population, were analyzed. The anti-TNF-o. drugs used to treat the selected patients were etanercept, 50mg once a week, adalimumab, 40mg once every two weeks, and infliximab, 3-5mg/kg every 6-8 weeks, following normal therapeutic schedules. Tolerance was analyzed by examining drug retention rates of the anti-TNF-a agents over the period until drug discontinuation, independently of the reason for drug interruption. Drug survival reflects patients' and doctors' satisfaction with a given treatment and therefore represents a useful summary measure of the overall effectiveness and tolerability of the treatment.
Only patients aged 65 years or more under therapy with an anti-TNF-a agent with at least I drug injection and with a diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or psoriasis were included in this multicenter retrospective study.
Patients with a diagnosis of inflammatory arthritis different from RA, PsA or AS were excluded from the study. All patients using other kinds of anti-TNF-a agents or other biologic medicines were not included in the study. All patients using different doses from the ones mentioned were not included in the study.
Furthermore, we analyzed survival rates of anti-TNF agents, classifying patients by disease. Finally, we also analyzed the rates of AEs leading to discontinuation, temporary or permanent, grouping the population by the anti-TNF agent taken. Data from patients affected by inflammatory arthritis and psoriasis who received at least one dose of therapy with an anti-TNF-a agent were reviewed, and episodes of temporary or permanent discontinuation were analyzed. Basic demographic data were recorded along with specific reasons for discontinuation, which were categorized into lack of efficacy, allergic reaction, severe infection, neoplasia, severe cardiovascular disease and other reasons. Allergic reactions were categorized into mild (urticaria, local rash), moderate (asthma, angioedema) or severe (anaphylactic shock or anaphylactoid reaction). Infections were categorized as follows: mild when patient reported an infectious episode with fever that resolved without the intake of antibiotics; moderate when the infectious episode required the use of antibiotics and/or antipyretics, while severe infections were characterized by the need for hospitalization. Cardiovascular diseases and neoplasia were all categorized as severe adverse events.
RESULTS
At the end of November 2007, 356 patients of 65 years or more affected by RA, PsA, AS or Ps, having had at least 1 anti-TNF-a injection and at least one set of follow-up data were included in the study. Age ranging was 65-89. 138 patients were affected by RA, 109 females and 29 males, mean duration of disease 11.6±7.8 years, 72 patients were affected by PsA, 42 females and 30 males, mean duration of disease 7.8±3.1 years, 34 patients were affected by AS, 7 females and 27 males, mean duration of disease 11±5 years, and 112 patients were affected by Ps, 52 females and 60 males, mean duration of disease 18A±9.8 years. 100% of patients affected by every kind of arthritis underwent DMARDs-based treatment before the first anti-TNF injection, while of the 112 Ps affected patients, only 87 (77.67%) underwent DMARDs-based therapy before the first anti-TNF injection. Nine patients affected by RA underwent previous anti-TNF therapy that was interrupted due to lack of efficacy before the course oftherapy analyzed in this paper. Similarly, 8 patients affected by PsA, 13 patients affected by AS and 11 patients affected by Ps underwent unsuccessful anti-TNF therapy, due to lack of efficacy of the first course of therapy, before beginning a second round of anti-TNF agent therapy, that is the object of the present study. The ICED score (index for co-existing diseases) was also calculated for every subgroup. Demographical and clinical data, age and disease subgroups, medication data of the patients included in the study and ICED scores are shown in Tables I, n and Fig. 1 .
Infectious and allergic AEs leading to permanent or temporary discontinuation of anti-TNF therapy are shown in Tables III and IV and in Figs. 1 and 2. Among Allergic reactions and Infections, in our experience, only severe events caused a temporary interruption of anti-TNF therapy, while all other AEs were sufficient to determine a permanent discontinuation of the therapy. No statistical correlation was observed for allergic or infectious AEs with glucocorticoid consumption in the global population or in disease-subgroups of patients. Two episodes of neoplasia occurred in the cohort of patients, 1 melanoma in a 68-year-old woman affected by Ps and under therapy with etanercept, and 1 lung cancer in a 72-year-old man affected by AS and under therapy with infliximab. Three patients manifested cardiovascular disease during the course of therapy with anti-TNF agents, 3 episodes of cardiac infarction, 1 in a 78-year-old woman affected by PsA and under therapy with infliximab, 1 in a 76year-old man affected by AS under therapy with ada1imumab and 1 in a 77-year-old man affected by Ps under therapy with etanercept. Among other AEs, we found a single patient, a 71-year-old woman, who reported a nephrotic syndrome during therapy with adalimumab for AS. We were also able to collect data regarding lack of efficacy in the elderly patients of this study who underwent anti-TNF therapy. A total of 24 patients, 10 for ETanercept (5.78% of treated patients), 5 for ada1imumab (6.67% of patients treated) and 8 for infliximab (7Al % of patients treated) reported lack of efficacy of the anti-TNF therapy after at least 2 months of therapy, as evaluated by DAS28, Sharp score and laboratory parameters. The distribution of patients who showed a lack of efficacy of the therapy is equal in therapy subgroups as for disease subgroups.
DISCUSSION
This IS a multicentric, retrospective study investigating the occurrence of adverse events among a population of elderly patients affected by arthritis or psoriasis and under therapy with anti-TNF-a agents to establish the incidence of adverse events. Elderly individuals make up a substantial proportion of RA, PsA, AS and Ps affected patients, but in current literature specific information regarding the safety of biologic DMARDs is still scarce and mainly derives from highly selected patients included in larger clinical trials (19) (20) (21) (22) . In this study, we report the safety-related results obtained from a large population of elderly patients affected by RA, PsA, AS or Ps undergoing an anti-TNF-a-based therapy. Our data show a good tolerance profile among the entire population, with rates of incidence of cardiovascular or malignant adverse events no different from healthy individuals (Table V) . In our population, infections are the major Total number ofpatients, subgroups categorized by disease, age subgroup and mean age in years. Subgroups ofpatients by treatment and age subgroup, with mean duration ofdisease in years and mean duration ofcurrent anti-TNF treatment in months, ± SD. 
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DMARD treatment previous to current anti-TNF therapy in the subgroups ofpatients. MTX = Methotrexate, LFL = Lefiunomide, SSZ = Salazopyrin, HCQ = Hydroxychloroquine, GC = Glucocorticoids, CyA = A-Cyclosporin cause of temporary or permanent discontinuation of biologic DMARDs treatment, followed by allergic reactions. In this study, we decided to investigate even the occurrence of mild adverse events, such as mild infections or mild allergic reactions, that may lead to temporary discontinuation of therapy and therefore pose safety concerns in clinical practice. Cardiovascular events reported in this study are represented by three cardiac infarctions, while no cardiovascular failures were reported. All three patients were undergoing anti-TNF therapy associated with methotrexate therapy. After the infarction, all three patients discontinued anti-TNF therapy. Ischemic cardiopathy is frequent among elderly patients and the occurrence of cardiac infarction in our population does not seem to be related to anti-TNF therapy. Screening patients for class IV heart failure previous to the initiation of anti-TNF therapy seems to allow, even in elderly patients, to reduce the incidence of anti-TNF-related heart failure adverse events.
Malignancies occurred in two patients undergoing anti-TNF therapy, a melanoma and a lung cancer. The patient who developed melanoma was affected by psoriasis and under therapy with an anti-TNF agent associated with a low dose of corticosteroids. The patient who developed lung cancer was under therapy with an anti-TNF agent and an association of methotrexate and cyclosporine. The patient was also a heavy smoker. Solid tumors, like the ones we observed in our patients, do not seem to relate to anti-TNF therapy, as stated in the literature regarding biologic DMARDs (23) . Again, we think that this incidence of solid malignancies does not differ from that typical of healthy patients of the same age. Screening patients for malignancies before anti-TNF therapy remains necessary.
Other severe adverse events reported by the patients consist injust one nephrotic syndrome, which occurred in a female undergoing anti-TNF therapy for AS. No otherco-medications could explain a nephrotic syndrome, and the origin of the disease in this patient remains uncertain, but does not seem to relate to the basal disease or to the therapy. Though recent studies seem to prove the efficacy of anti-TNF therapy in patients affected by nephrotic syndrome, in our patient the therapy did not seem to protect her from the occurrence of nephrotic syndrome (24) . At the time of insurgence of nephrotic syndrome, the patient was under therapy with anti-TNF agent, low dose ASA and corticosteroids.
Allergic reactions occurred among all age groups and all basal diseases subsequent to anti-TNF therapy, but the highest rate of allergic reactions was observed in patients affected by AS. We mainly observed mild or moderate reactions in all patients, except for one severe allergic reaction that occurred in a patient affected by RA, requirin g hospitalization. The patient reported severe acute dyspnea, and signs of urticaria and angioedema were observable. The patient also referred that it was the first occasion of acute dyspnea and that this was the first acute allergic reaction he could remember. Family history of atopy was also negative. The hospitalization lasted for 7 days, and both corticosteroids and antihistamine drugs were needed in order to reduce the symptoms.
Infections were the most frequent adverse events observed in our population, leading to temporary or permanent discontinuation of anti-TNF therapy (25) . 45 Fig. 3 . Percentages ofpatients reporting an allergic reaction during anti-TNF therapy. Patients have been categorized for disease, and for every disease we categorized reactions into mild, moderate and severe. In each disease group, the total percentage represents the percentage ofpatients reporting an allergic reaction. The total percentage is then distributed into the kind ofallergic reaction, mild, moderate or severe.
Mainly, we observed mild infections that did not even require antibiotic therapy, such as flu-like syndrome, but also pharyngotonsillitis, bronchitis, and cystitis, the latter often requiring antibiotics. The incidence of mild or moderate infections does not seem to differ from that observed in a healthy population ofthe same age. Interestingly, infections occurred more often in AS-affected patients. We observed only two cases of severe infections requiring hospitalization: two cases of bronchial pneumonia unrelated to tuberculosis, that was resolved with short hospitalization and antibiotic therapy. These two patients decided to withdraw from the anti-TNF therapy. Such infectious events are not uncommon in elderly patients and we suppose that the incidence of infections we observed in our population does not differ from the incidence observable in healthy populations of the same age. As expected, a larger number of patients reporting an infectious adverse event was observed in ASaffected patients, and a high percentage of infections in this subgroup was represented by high and low respiratory tract infections. Screening patients for tuberculosis before the beginning of anti-TNF therapy still remains a valid strategy for avoiding severe and possibly damaging infections, such as those caused by Bacillus tuberculosis.
Our secondary endpoint was to evaluate any differences in the incidence of adverse events in the three age groups: 65 to 70 years, 71 to 75 years and 76 or more years. We did not notice any differences between the age groups regarding incidence of adverse events, except for the episodes of severe infection and of cardiovascular events, both of which occurred in the 76 or more age group. By contrast, allergic reactions seem to occur more often in younger patients, as reported in previous studies (26) , and in our population, patients of between 65 and 70 seemed to be more prone to developing allergic reactions to biologic DMARDs. The efficacy of anti-TNF agents in RA, AS, PsA and PS has been proved by several previous studies (7, 9-12, 14-15, 27-28) , and, specifically, the efficacy of anti-TNF agents in such pathologies affecting elderly patients has been the object of other more recent studies (19) (20) (21) . In this study, we focused our attention only on the safety of these therapeutic agents in elderly patients. Our results seem to suggest that anti-TNF agents are a good therapeutic option in patients affected by arthritis or psoriasis, because safety profiles in this class of patients are acceptable, there being no evidence, in our data, of any increases in the incidence of infections, cardiovascular events, malignancies or other diseases. Any allergic reactions we were able to observe in elderly patients undergoing anti-TNF therapy were almost exclusively mild, required no therapy, and were never life-threatening except in one case. The incidence of adverse events we observed is no different from that observed in other studies for younger patients. As a good profile of cost-effectiveness was observed in younger patients undergoing anti-TNF therapies, and as our data seem to suggest that the rate ofAEs is not different in this elderly population, we also suppose that, in terms of cost-effectiveness, the use of anti-TNF could grant a good profile in elderly patients as well, but such a supposition needs further studies on long-term effects to be clarified (28) (29) (30) .
This study does have its limitations, though. This is not an observational or comparative study, but a multicenter retrospective study. Patients undergoing biologic DMARDs therapy are not equally divided by pathology, as our population is mainly represented by RA-and Ps-affected patients, and the small number of AS-affected patients may be a limit in evaluating adverse event incidence related to anti-TNF agents in elderly patients affected by this disease. We classified allergic reactions as adverse events to anti-TNF agents only on the basis of our expenence.
In conclusion, our data show that admitting elderly patients into anti-TNF therapeutic regimens is a safe option and that it grants these patients access to the best current therapeutic option, possibly leading to better disease outcomes. Quality of life in elderly patients affected by arthritis or psoriasis, often reduced by comorbidities, is as important as quality of life in younger patients. Furthermore, life-expectation for the over 65s is increasing, and granting those patients the best therapeutic option is important for ethical and economic reasons as long as it does not represent a danger for the patients.
Applying the recommended screening before using biologic DMARDs helps to reduce adverse events related to the therapy, and the application of the same screening in elderly patients seems to lead to comparable results.
